Kyverna Therapeutics (KYTX) Preferred Stock Liabilities (2023)
Kyverna Therapeutics (KYTX) posted Preferred Stock Liabilities of $180.6 million for Q4 2023, little changed on a QoQ basis from $180.6 million in Q3 2023.
Kyverna Therapeutics (KYTX) Preferred Stock Liabilities (2023) Analysis & Trends
Kyverna Therapeutics' Preferred Stock Liabilities history runs 1 years deep, the most recent figure standing at $180.6 million for Q4 2023.
- Quarterly Preferred Stock Liabilities changed N/A year-over-year to $180.6 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $180.6 million (changed N/A YoY) and the FY2023 annual result came in at $180.6 million, changed N/A from the prior year.
- Preferred Stock Liabilities was $180.6 million for Q4 2023 at Kyverna Therapeutics, roughly flat from $180.6 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $180.6 million in Q3 2023 and bottomed at $120.7 million in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Kyverna Therapeutics | 447.52 Mn | 447.52 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 180.57 Mn |
| Sep 30, 2023 | 180.57 Mn |
| Jun 30, 2023 | 145.73 Mn |
| Mar 31, 2023 | 120.67 Mn |